BACKGROUND: We hypothesized that granulocyte macrophage colony-stimulating factor
(GM-CSF) administration will be safe and will improve endothelial dysfunction and exercise …

Importance Many patients with peripheral artery disease (PAD) have walking impairment
despite therapy. Experimental studies in animals demonstrate improved perfusion in …

Background The purpose of this study was to determine whether treatment with granulocyte
colony-stimulating factor (G-CSF), which mobilizes endothelial progenitor cells from bone …

Background Implantation of bone marrow mononuclear cells, including endothelial
progenitor cells, into ischemic limbs has been shown to improve collateral vessel formation …

Functional impairment, functional decline, and mobility loss are major public health
problems in people with lower extremity peripheral artery disease (PAD). Few medical …

Background: The clinical usefulness of peripheral blood (PB) mononuclear cell (MNC)
transplantation in patients with peripheral arterial disease (PAD), especially in those with …

Aim: Peripheral arterial disease (PAD), particularly critical limb ischemia (CLI), is a severe
cause of amputation and mortality. More than 50% of diabetic patients with CLI die within …

Peripheral artery disease (PAD) refers to noncoronary vascular disease affecting the
peripheral arteries. Most commonly the term is applied to occlusive arterial disease affecting …

Aims Despite considerable advances in the therapy of patients with peripheral arterial
occlusive disease (PAOD) and critical limb ischaemia (CLI), a substantial number remain, in …

Objective: Early-phase clinical trials suggest that autologous bone-marrow-derived cells
(BMCs) may have a positive effect on patients with severe peripheral arterial disease (PAD) …